Erlotinib-Lnduced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer

Annals of Pharmacotherapy

Volumn 43, Issue 3, 2009, Pages 542-545

  Pellegrinotti, Marco ^a   Fimognari, Filippo Luca ^b   Franco, Alessandro ^a   Repetto, Lazzaro ^b   Pastorelli, Ruggero ^c  

^a Leopoldo Parodi Delfino Hospital   (Italy)

^b Ospedale Leopoldo Parodi Delfino   (Italy)

^c INRCA   (Italy)

Author keywords

Acute liver failure; Drug induced hepatitis; Erlotinib, metformin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BICARBONATE; CARBOPLATIN; CREATININE; DOCETAXEL; DOXAZOSIN; ERLOTINIB; FUROSEMIDE; GEMCITABINE; INFUSION FLUID; INSULIN; METFORMIN; NITROGEN; OMEPRAZOLE; PREDNISONE; REPAGLINIDE; UREA; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DISEASE COURSE; ELDERLY CARE; ENZYME BLOOD LEVEL; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LACTIC ACIDOSIS; LIVER METASTASIS; LUNG ADENOCARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT FAILURE; ADENOCARCINOMA; DIABETES MELLITUS; FATALITY; LUNG TUMOR; TOXIC HEPATITIS;

ACIDOSIS, LACTIC; ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS; DRUG-INDUCED LIVER INJURY; FATAL OUTCOME; HUMANS; LUNG NEOPLASMS; MALE; METFORMIN; QUINAZOLINES;

EID: 62949194458     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L468     Document Type: Article

References (22)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
2. Herbst RS, Prager D, Hermann RR, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
3. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005;10:461-6.
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
5. Ramanarayanan J, Scarpace SL. Acute drug induced hepatitis due to erlotinib. JOP 2007;8:39-43.
6. Saif MW. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. Clin Adv Hematol Oncol 2008;6:191-9.
7. OSI Pharmaceuticals, Inc. and Genentech, Inc. Important safety information. www.gene.com/products/information/pdf/tarceva-dhcp-letter.pdf, posted October 2008 (accessed 2008 Nov 4).
8. Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007;5:917-20.
9. Runge S, Mayerle J, Warnke C, et al. Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? Diabetes Obes Metab 2008;10:91-3.
10. Fimognari FL, Corsonello A, Pastorelli R, Antonelli Incalzi R. Metformin-induced pancreatitis: a possible adverse drug effect during acute renal failure. Diabetes Care 2006;29:1183.
11. Bodmer M, Meier C, Krahenbiihl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis and hypoglycemia: a nested case-control analysis. Diabetes Care 2008;31:2086-91.
12. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984;2:187-93.
13. Pérez-Roldán F, Aguirre A, Bañares R, et al. Cholestatic hepatitis caused by glybenclamide in a patient with hepatitis C virus. Rev Esp Enferm Dig 1995;87:174-6.
14. López-García F, Borrás J, Verdú C, et al. Cholestatic hepatitis associated with repaglinide. Diabetes Care 2005;28:752-3.
15. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007;30: 277-94.
16. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;11:1323-30.
17. Lee WM. Acute liver failure. Am J Med 1994;96(suppl):3S-9S.
18. Targeted agents in the treatment of elderly patients with non-small-cell lung cancer: an expert interview with Dr. Thomas Lynch. Medscape Hematol Oncol 2006, March 24. www.medscape.com (accessed 2008 Apr 28).
19. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-6.
20. Langer CJ. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non- small-cell lung cancer. J Clin Oncol 2007;25:751-3.
21. Corsonello A, Pedone C, Corica F, Mussi C, Antonelli Incalzi R. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005;165:790-5.
22. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-9.